We’re glad to see you’re enjoying ReachMD…but how about a more personalized experience?
Experts from the U.S. Food and Drug Administration (FDA) discuss important new drug information as well as urgent insights about approved drug products.
The FAERS Public Dashboard and its Value to the Pharmaceutical Industry
FDA Warns of Serious Immune Reaction with Seizure/BPD Medicine Lamotrigine (Lamictal)
FDA’s Role in Foreign Drug Manufacturing
FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer
FDA Requires New Class Warnings for All Gadolinium-Based Contrast Agents
FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk
The FDA's Adverse Event Reporting System (FAERS) Public Dashboard
FDA D.I.S.C.O.: L-Glutamine for Sickle Cell Disease
FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer
FDA D.I.S.C.O.: Two Approvals for ALK-Positive Non-Small Cell Lung Cancer
FDA D.I.S.C.O.: First Tissue/Site Agnostic Cancer Treatment Approval
FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma
FDA D.I.S.C.O.: Niraparib in Ovarian Cancer
FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer
FDA Confirms Leg and Foot Amputation Risk with Diabetes Medicine Canagliflozin
Assessing the Pros of Patient-Reported Outcomes in Early Breast Cancer
You need to be logged in to save this episode to a playlist.
Press cancel to remain on ReachMD. Press the link below or the continue button to keep going.
Stay current with the best on medical education